在感染 HIV 的乌干达成年人中，不同用餐条件下给予洛匹那韦利托那韦时的稳态药代动力学。
Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.
机构信息
Research Department, Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
出版信息
J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):295-8. doi: 10.1097/QAI.0b013e3182567a35.
Abstract
We investigated the effect of food on the steady-state pharmacokinetics of lopinavir and ritonavir in 12 Ugandan patients receiving lopinavir coformulated with ritonavir (LPV/r) tablets using a crossover design. Intensive pharmacokinetic sampling was performed 7 days apart after LPV/r dosing under moderate fat, high fat, and fasted meal conditions. Lopinavir and ritonavir concentrations were determined by liquid chromatography and tandem mass spectrometry. Compared with the fasted state, a high fat meal reduced lopinavir and ritonavir area under the curve by 14% and 29%, respectively. With a moderate fat meal, area under the curve for both drugs was similar to the fasted state.
摘要
我们采用交叉设计，在 12 例接受洛匹那韦利托那韦复方制剂（LPV/r）治疗的乌干达患者中，研究了食物对洛匹那韦和利托那韦稳态药代动力学的影响。LPV/r 给药后 7 天，在中等脂肪、高脂肪和禁食餐条件下，分别进行密集的药代动力学采样。洛匹那韦和利托那韦浓度通过液相色谱-串联质谱法测定。与禁食状态相比，高脂肪餐使洛匹那韦和利托那韦的曲线下面积分别减少了 14%和 29%。中等脂肪餐时，两种药物的曲线下面积与禁食状态相似。
相似文献
1
Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.
J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):295-8. doi: 10.1097/QAI.0b013e3182567a35.
2
The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):148-54. doi: 10.1097/QAI.0000000000000135.
3
Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir.
Int J Infect Dis. 2013 Oct;17(10):e857-61. doi: 10.1016/j.ijid.2013.02.017. Epub 2013 Apr 12.
4
Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.
J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):55-8. doi: 10.1097/QAI.0b013e31823ba736.
5
No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.
Antimicrob Agents Chemother. 2015 Nov 2;60(1):400-8. doi: 10.1128/AAC.01197-15. Print 2016 Jan.
6
The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals.
Int J Tuberc Lung Dis. 2015 Oct;19(10):1194-6. doi: 10.5588/ijtld.15.0044.
7
Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.
Br J Clin Pharmacol. 2012 May;73(5):758-67. doi: 10.1111/j.1365-2125.2011.04154.x.
8
Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.
J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):385-91. doi: 10.1097/QAI.0b013e318232b057.
9
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.00420-17. Print 2018 Feb.
10
Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir.
J Antimicrob Chemother. 2012 Dec;67(12):2927-31. doi: 10.1093/jac/dks332. Epub 2012 Aug 23.
引用本文的文献
1
Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses.
AIDS Behav. 2023 May;27(5):1441-1468. doi: 10.1007/s10461-022-03880-6. Epub 2022 Nov 1.
2
"That's True Love:" Lived Experiences of Puerto Rican Perinatally HIV-Infected Youth within Their Families' Context.
Int J Environ Res Public Health. 2015 Dec 22;13(1):ijerph13010007. doi: 10.3390/ijerph13010007.
3
The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
Pediatr Infect Dis J. 2015 Mar;34(3):e63-70. doi: 10.1097/INF.0000000000000603.
4
Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.
J Clin Pharmacol. 2014 Feb;54(2):121-32. doi: 10.1002/jcph.167. Epub 2013 Sep 21.
本文引用的文献
1
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jun 1;878(19):1455-65. doi: 10.1016/j.jchromb.2010.03.036. Epub 2010 Apr 9.
2
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
Clin Pharmacol Ther. 2008 Jul;84(1):75-82. doi: 10.1038/sj.clpt.6100452. Epub 2008 Jan 9.
3
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.
J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):401-10. doi: 10.1097/QAI.0b013e31803133c5.
4
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
N Engl J Med. 1998 Mar 26;338(13):853-60. doi: 10.1056/NEJM199803263381301.
Zotero 插件